Sugi Predict

Sugi Predict / Compounds / SCHEMBL29682467

SCHEMBL29682467

SCHEMBL29682467

CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 4/20 0.52
▸ NPY1R P25929 3/20 0.52
▸ NPY2R P49146 3/20 0.52
▸ ERAP2 Q6P179 1/20 0.47
▸ ERAP1 Q9NZ08 1/20 0.47
▸ LNPEP Q9UIQ6 1/20 0.47
▸ GSR P00390 1/20 0.47
▸ DPP8 Q6V1X1 1/20 0.46
▸ DPP9 Q86TI2 1/20 0.46
▸ DPP7 Q9UHL4 1/20 0.46
▸ CPB2 Q96IY4 4/20 0.46
▸ NTSR2 O95665 2/20 0.46
▸ NTSR1 P30989 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ FOLH1 Q04609 2/20 0.45
▸ NPY5R Q15761 2/20 0.44
▸ NMT2 O60551 1/20 0.44
▸ NMT1 P30419 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29630471 0.99 NPY4R (0.53) NPY4RNPY1RNPY2RERAP2ERAP1
Sinapultide SCHEMBL29360133 0.96 NPY4R (0.53) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL31343363 0.96 NPY4R (0.53) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL31343323 0.96 NPY4R (0.53) NPY4RNPY1RNPY2RERAP2ERAP1
Sinapultide SCHEMBL180504 0.96 NPY4R (0.53) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL31343405 0.96 NPY4R (0.53) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL29740735 0.96 NPY1R (0.50) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL30397735 0.96 NPY1R (0.50) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL8013829 0.96 GSR (0.51) NPY4RNPY1RNPY2RERAP2ERAP1
SCHEMBL20818872 0.96 GSR (0.51) NPY4RNPY1RNPY2RERAP2ERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024059686-A2 DARPIN BACKBONES AND RIGIDIFIED ELECTRON MICROSCOPY IMAGING SCAFFOLDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 — — WO claimed
US-20260098271-A1 METHOD FOR INCREASING RECOMBINANT PROTEIN EXPRESSION HOFFMANN-LA ROCHE INC. (US) 2026-04-09 — — US disclosed
US-20250385825-A1 Turbo Decision Feedback Equalizer and Decoder (TDFED) for Orthogonal Time Frequency Space (OTFS) Communication Systems UNIV LEHIGH (US) 2025-12-18 — — US disclosed
US-20250382625-A1 SYNTHETIC PRE-PROTEIN SIGNAL PEPTIDES FOR DIRECTING SECRETION OF HETEROLOGOUS PROTEINS IN ESCHERICHIA BACTERIA TENZA INC (US) 2025-12-18 — — US disclosed
US-20250368993-A1 Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof IONIS PHARMACEUTICALS, INC. (US) 2025-12-04 — — US disclosed
EP-4623086-A1 METHOD FOR INCREASING RECOMBINANT PROTEIN EXPRESSION F. Hoffmann-La Roche AG (CH) 2025-10-01 — — EP disclosed
EP-3596102-B1 STRUCTURE-BASED PEPTIDE INHIBITORS THAT TARGET THE TAU VQIINK FIBRILLIZATION SEGMENT UNIV CALIFORNIA (US) 2025-09-10 — — EP disclosed
WO-2024110426-A1 METHOD FOR INCREASING RECOMBINANT PROTEIN EXPRESSION F. HOFFMANN-LA ROCHE AG (CH) 2024-05-30 — — WO disclosed
WO-2024059686-A2 DARPIN BACKBONES AND RIGIDIFIED ELECTRON MICROSCOPY IMAGING SCAFFOLDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 — — WO disclosed
CN-117460537-A Nucleic acid delivery 信使治疗公司 2024-01-26 — — CN disclosed
US-20230121967-A1 Oligomeric Compounds Comprising Bicyclic Nucleotides and Uses Thereof IONIS PHARMACEUTICALS, INC. (US) 2023-04-20 — — US disclosed
CN-114592023-B Cell lysis self-assembly polypeptide compound, self-assembly method, self-assembly polypeptide preparation and application 杭州优玛达生物科技有限公司 2023-03-24 — — CN disclosed
US-20230033133-A1 VACCINE CONJUGATES ULTIMOVACS AB (SE) 2023-02-02 — — US disclosed
US-11566245-B2 Oligomeric compounds comprising bicyclic nucleotides and uses thereof IONIS PHARMACEUTICALS, INC. (US) 2023-01-31 — — US disclosed
CN-115427437-A Novel immunologically active interleukin-2 analogs 韩美药品株式会社 2022-12-02 — — CN disclosed
EP-4069283-A1 VACCINE CONJUGATES Ultimovacs AB (SE) 2022-10-12 — — EP disclosed
EP-4049846-A1 DEVICE AND METHOD FOR PRINTING ON ONE OR BOTH SIDES OF A PLURALITY OF FLAT OBJECTS Mühlbauer GmbH & Co. KG (DE) 2022-08-31 — — EP disclosed
US-20220266607-A1 DEVICE AND METHOD FOR PRINTING ON ONE OR BOTH SIDES OF A PLURALITY OF FLAT OBJECTS Muehlbauer GmbH & Co. KG (DE) 2022-08-25 — — US disclosed
CN-114901305-A Vaccine conjugates 乌尔蒂莫瓦科斯公司 2022-08-12 — — CN disclosed
CN-114592023-A Cell lysis self-assembly polypeptide compound, self-assembly method, self-assembly polypeptide preparation and application 杭州优玛达生物科技有限公司 2022-06-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230033133-A1 VACCINE CONJUGATES KLK3, CD4, CD74 NPY4R 3519/4885NPY1R 3223/4885NPY2R 3473/4885
US-20260098271-A1 METHOD FOR INCREASING RECOMBINANT PROTEIN EXPRESSION SPPL2A, SPPL2B, RNPEP NPY4R 1234/4885NPY1R 1168/4885NPY2R 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.